Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The firm's 300 Series product candidates include COYA 301 and COYA 302.
Follow-Up Questions
Who is the CEO of Coya Therapeutics Inc?
Dr. Arun Swaminathan is the Chief Executive Officer of Coya Therapeutics Inc, joining the firm since 2024.
What is the price performance of COYA stock?
The current price of COYA is $5.97, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Coya Therapeutics Inc?
Coya Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Coya Therapeutics Inc market cap?
Coya Therapeutics Inc's current market cap is $99.9M
Is Coya Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Coya Therapeutics Inc, including 3 strong buy, 9 buy, 1 hold, 0 sell, and 3 strong sell
